A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.
about
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionTargeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platformCD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT miceChemically Programmed Bispecific Antibodies in Diabody Format.Recent developments in immunotherapy of acute myeloid leukemia."NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infectionAcute myeloid leukemia targets for bispecific antibodies.Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.Emerging therapies for acute myeloid leukemia: translating biology into the clinic.Antibody darts on target for acute myelogenous leukemia.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.Redirecting T cells to hematological malignancies with bispecific antibodies.A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies.Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.Bispecific antibodies in cancer immunotherapy.Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
P2860
Q30360904-B8E2BB7F-DF36-4D0C-8F0D-5AF6258A2BABQ30827633-693C4DE8-6C9B-44E1-9C85-1A6D7D38558CQ33620546-046326FF-F7B3-431C-9B44-690F4E6ED581Q35833324-26338780-AAF8-459D-B900-0CEE7A28FD66Q36266486-1B48DDB4-7795-449E-887C-63D23D2938CFQ36443107-D8E0AE35-6C83-4099-A3A0-E8E2EF79BD57Q36777155-E0651D81-8336-4F72-9C99-F157BB36F6B9Q38436973-B096CEE0-9091-411C-8C89-AE94FA2A3AB3Q38661895-55D622DF-29A0-4F76-B7B3-089EC709B869Q38723957-54DAAEC0-A2A9-4BCD-AA9B-EE9FB6C843AAQ38727986-BACC9A33-0226-455A-94B0-150FB6996680Q38758807-172ED272-2DFD-434C-ADB9-0F36347A9394Q38891877-F3C887B8-4424-4C66-A930-48C838BA5D2DQ38977425-74FDA8F8-44C9-4F63-8EA4-107CD4054789Q39117761-03EB344C-29FD-4DE2-A3F8-39C6D3BAC294Q40314122-16F2C939-0714-4284-A746-5322F737EF06Q41573313-9F837F60-912A-447C-95EA-B5A257D17B79Q41984963-89ED9E1B-0FAD-4C48-A0DB-DF869C71AF94Q42318343-5C81566C-2694-4317-BCA7-2973A5605275Q47570404-0AF2560C-8B0A-4725-B29A-192EDAB6341EQ47607160-F8BAEC8B-E877-47C0-8DC4-760BF912B12BQ47696309-CE07FC30-B3D7-40A3-9E6D-281D4D490FCAQ48339827-E432B119-FDA7-4EEE-BF9A-B1500802F88FQ49918596-811ED4F4-1D7F-4AFD-AEB2-CC37FE9AF4DDQ50581082-67D824C3-F07D-40EC-AAFD-9D0F587AF1D0Q51309023-C8DA5815-7039-4BE7-AD05-C006551E4F16Q52597560-93F5386E-18A0-4733-B7BB-DEEE3219D918Q55354182-4F2625EF-F8F3-4F40-B629-CDAB19E0A6B2Q57174193-BA186FA9-F0C2-44AF-BF4A-C9D41D75042E
P2860
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A CD3xCD123 bispecific DART fo ...... d safety in nonhuman primates.
@ast
A CD3xCD123 bispecific DART fo ...... d safety in nonhuman primates.
@en
type
label
A CD3xCD123 bispecific DART fo ...... d safety in nonhuman primates.
@ast
A CD3xCD123 bispecific DART fo ...... d safety in nonhuman primates.
@en
prefLabel
A CD3xCD123 bispecific DART fo ...... d safety in nonhuman primates.
@ast
A CD3xCD123 bispecific DART fo ...... d safety in nonhuman primates.
@en
P2093
P1476
A CD3xCD123 bispecific DART fo ...... d safety in nonhuman primates.
@en
P2093
Ezio Bonvini
Francine Chen
Gurunadh R Chichili
Ling Huang
Michele Shannon
Paul A Moore
P304
P356
10.1126/SCITRANSLMED.AAA5693
P407
P577
2015-05-01T00:00:00Z